Gene Therapy Treatments for Sickle Cell Disease - MEDICAID - SOUTH CAROLINA

Covers autologous hematopoietic stem cell–based gene therapies for sickle cell disease (e.g., Casgevy/exagamglogene autotemcel and Lyfgenia/lovotibeglogene autotemcel) including HSC collection, ex vivo gene modification, conditioning, and reinfusion. Indicated for individuals aged ≥12 (document lists up to 65) with SCD and recurrent vaso-occlusive crises (generally ≥2 severe VOCs per year for the prior 2 years) who are candidates for autologous HSCT but lack a matched donor and have no contraindications; coverage is limited to these specified autologous gene‑therapy approaches and may be subject to member‑specific plan provisions.

"Sickle cell disease (SCD) caused by abnormal hemoglobin S (HbS) or sickle hemoglobin (as described in the document)."

Sign up to see full coverage criteria, indications, and limitations.